Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: PLoS ONE, 9, 9, S. e107297-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2014
- Ereignis
-
Veröffentlichung
- (wer)
-
Public Library of Science (PLoS)
- (wann)
-
2014
- Urheber
-
Szkandera, Joanna
Gerger, Armin
Liegl-Atzwanger, Bernadette
Stotz, Michael
Samonigg, Hellmut
Ploner, Ferdinand
Stojakovic, Tatjana
Leithner, Andreas
Pichler, Martin
- DOI
-
10.1371/journal.pone.0107297
- URN
-
urn:nbn:de:bvb:384-opus4-1036391
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:41 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Szkandera, Joanna
- Gerger, Armin
- Liegl-Atzwanger, Bernadette
- Stotz, Michael
- Samonigg, Hellmut
- Ploner, Ferdinand
- Stojakovic, Tatjana
- Leithner, Andreas
- Pichler, Martin
- Universität Augsburg
- Public Library of Science (PLoS)
Entstanden
- 2014
Ähnliche Objekte (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients
Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
The pre-treatment c-reactive protein represents a prognostic factor in patients with oral and oropharyngeal cancer treated with radiotherapy
MicroRNAs in different histologies of soft tissue sarcoma: a comprehensive review
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients
Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
The pre-treatment c-reactive protein represents a prognostic factor in patients with oral and oropharyngeal cancer treated with radiotherapy
MicroRNAs in different histologies of soft tissue sarcoma: a comprehensive review
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Best of ASCO 2022: bladder cancer
Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients
Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma
The pre-treatment c-reactive protein represents a prognostic factor in patients with oral and oropharyngeal cancer treated with radiotherapy
MicroRNAs in different histologies of soft tissue sarcoma: a comprehensive review
Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1